Free tool
FAERS Monitor: Ziagen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020978 or its brand name (Ziagen, Abacavir Sulfate). Reports on generic versions are filed under their own applications.
Reports
4,037
Serious
3,693
91% of reports
Hospitalization
1,582
Death reported
501
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain748
- pyrexia501
- hypertension425
- anxiety419
- hepatic enzyme increased410
- emotional distress409
- headache404
- hypersensitivity399
- off label use396
- anhedonia368
- fatigue367
- exposure during pregnancy359
- rash352
- immunodeficiency328
- nausea326
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 300 |
| 2005 | 262 |
| 2006 | 221 |
| 2007 | 200 |
| 2008 | 222 |
| 2009 | 235 |
| 2010 | 177 |
| 2011 | 105 |
| 2012 | 128 |
| 2013 | 117 |
| 2014 | 123 |
| 2015 | 158 |
| 2016 | 142 |
| 2017 | 121 |
| 2018 | 115 |
| 2019 | 253 |
| 2020 | 274 |
| 2021 | 154 |
| 2022 | 175 |
| 2023 | 147 |
| 2024 | 186 |
| 2025 | 148 |
| 2026 | 74 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,122 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| immunodeficiencySignal | 328 | 117.2 | 105.5 | 36,863 |
| anhedoniaSignal | 368 | 74.0 | 67.1 | 26,082 |
| hepatic enzyme increasedSignal | 410 | 31.5 | 28.7 | 12,051 |
| exposure during pregnancySignal | 359 | 30.3 | 27.4 | 10,100 |
| emotional distressSignal | 409 | 17.7 | 16.1 | 6,426 |
| hypersensitivitySignal | 399 | 11.2 | 10.2 | 3,729 |
| hypertensionSignal | 425 | 10.5 | 9.6 | 3,662 |
| anxietySignal | 419 | 7.7 | 7.0 | 2,458 |
| pyrexiaSignal | 501 | 7.6 | 7.0 | 2,885 |
| painSignal | 748 | 6.4 | 6.0 | 3,464 |
| rashSignal | 352 | 4.2 | 3.8 | 876 |
| headacheSignal | 404 | 3.4 | 3.1 | 687 |
| fatigueSignal | 367 | 2.5 | 2.2 | 327 |
| off label useSignal | 396 | 2.4 | 2.1 | 321 |
| nauseaSignal | 326 | 2.1 | 1.9 | 206 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.